The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes
Abstract
OBJECTIVE: This study assessed the efficacy and safety of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, as add-on to insulin in adults with type 1 diabetes. RESEARCH DESIGN AND METHODS: This 18-week, double-blind, phase 2 study randomized 351 patients (HbA1c 7.0–9.0% [53–75 mmol/mol]) on multiple daily insulin injections or continuous subcutaneous insulin infusion to canagliflozin 100 or 300 mg or placebo. The primary end point was the proportion of patients achieving at week 18 both HbA1c reduction from baseline of ≥0.4% (≥4.4 mmol/mol) and no increase in body weight. Other end points included changes in HbA1c, body weight, and insulin dose, as well as hypoglycemia incidence. Safety was assessed by adverse event (AE) reports. RESULTS: More patients had both HbA1c reduction ≥0.4% and no increase in body weight with canagliflozin 100 and 300 mg versus placebo at week 18 (36.9%, 41.4%, 14.5%, respectively; P < 0.001). Both canagliflozin doses provided reductions in HbA1c, body weight, and insulin dose versus placebo over 18 weeks. The incidence of hypoglycemia was similar across groups; severe hypoglycemia rates were low (1.7–6.8%). Overall incidence of AEs was 55.6%, 67.5%, and 54.7% with canagliflozin 100 and 300 mg and placebo; discontinuation rates were low (0.9–1.3%). Increased incidence of ketone-related AEs (5.1%, 9.4%, 0%), including the specific AE of diabetic ketoacidosis (DKA) (4.3%, 6.0%, 0%), was seen with canagliflozin 100 and 300 mg versus placebo. CONCLUSIONS: Canagliflozin provided reductions in HbA1c, body weight, and insulin dose with no increase in hypoglycemia, but increased rates of ketone-related AEs, including DKA, in adults with type 1 diabetes inadequately controlled with insulin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M. B., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 965
Peters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670
Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010
Livingstone, S. J., Levin, D., Looker, H. C., Lindsay, R. S., Wild, S. H., Joss, N., Leese, G., Leslie, P., McCrimmon, R. J., Metcalfe, W., et al. (2015) · JAMA · doi:10.1001/jama.2014.16425 · Cited by 621
Borus, J. S., & Laffel, L. (2010) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32833a46a7 · Cited by 353
Cited by
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
DeFronzo, R. A., Norton, L., & Abdul-Ghani, M. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.170 · Cited by 553
Dhatariya, K. K., Glaser, N. S., Codner, E., & Umpierrez, G. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0165-1 · Cited by 461
Effects of sotagliflozin added to insulin in patients with type 1 diabetes
Garg, S. K., Henry, R. R., Banks, P., Buse, J. B., Davies, M. J., Fulcher, G. R., Pozzilli, P., Gesty-Palmer, D., Lapuerta, P., Simó, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708337 · Cited by 417
Self-citationDanne, T., Garg, S., Peters, A. L., Buse, J. B., Mathieu, C., Pettus, J. H., Alexander, C. M., Battelino, T., Ampudia-Blasco, F. J., Bode, B. W., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2316 · Cited by 379
Self-citationHandelsman, Y., Henry, R. R., Bloomgarden, Z. T., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Ferrannini, E., Fonseca, V. A., Garber, A. J., Grunberger, G., et al. (2016) · Endocrine Practice · doi:10.4158/ep161292.ps · Cited by 358
Self-citationGoldenberg, R. M., Berard, L. D., Cheng, A. Y. Y., Gilbert, J. D., Verma, S., Woo, V. C., & Yale, J.-F. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.11.002 · Cited by 354
Emerging role of SGLT-2 inhibitors for the treatment of obesity
Pereira, M. J., & Eriksson, J. W. (2019) · Drugs · doi:10.1007/s40265-019-1057-0 · Cited by 342
Development of SGLT1 and SGLT2 inhibitors
Rieg, T., & Vallon, V. (2018) · Diabetologia · doi:10.1007/s00125-018-4654-7 · Cited by 377
Buzzetti, R., Tuomi, T., Mauricio, D., Pietropaolo, M., Zhou, Z., Pozzilli, P., & Leslie, R. D. (2020) · Diabetes · doi:10.2337/dbi20-0017 · Cited by 305
Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data
Blau, J. E., Tella, S. H., Taylor, S. I., & Rother, K. I. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2924 · Cited by 271
Carbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 267
Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms
Corbin, K. D., Driscoll, K. A., Pratley, R. E., Smith, S. R., Maahs, D. M., Mayer-Davis, E. J., & Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON) (2018) · Endocrine Reviews · doi:10.1210/er.2017-00191 · Cited by 262
Mathieu, C., Dandona, P., Gillard, P., Senior, P., Hasslacher, C., Araki, E., Lind, M., Bain, S. C., Jabbour, S., Arya, N., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0623 · Cited by 252
Dandona, P., Mathieu, C., Phillip, M., Hansen, L., Tschöpe, D., Thorén, F., Xu, J., Langkilde, A. M., DEPICT-1 Investigators, Proietto, J., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1087 · Cited by 243
Buse, J. B., Garg, S. K., Rosenstock, J., Bailey, T. S., Banks, P., Bode, B. W., Danne, T., Kushner, J. A., Lane, W. S., Lapuerta, P., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0343 · Cited by 234
Euglycemic diabetic ketoacidosis: etiologies, evaluation, and management
Long, B., Lentz, S., Koyfman, A., & Gottlieb, M. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2021.02.015 · Cited by 150
SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: Balancing benefits and risks
Taylor, S. I., Blau, J. E., Rother, K. I., & Beitelshees, A. L. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30154-8 · Cited by 124
McCoy, R. G., Dykhoff, H. J., Sangaralingham, L., Ross, J. S., Karaca-Mandic, P., Montori, V. M., & Shah, N. D. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0213 · Cited by 122
Bonora, B. M., Avogaro, A., & Fadini, G. P. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13012 · Cited by 118
Peters, A. L., Henry, R. R., Thakkar, P., Tong, C., & Alba, M. (2016) · Diabetes Care · doi:10.2337/dc15-1995 · Cited by 106
Self-citationA safety update on sodium glucose co-transporter 2 inhibitors
Fitchett, D. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13611 · Cited by 99
Rodbard, H. W., Peters, A. L., Slee, A., Cao, A., Traina, S. B., & Alba, M. (2017) · Diabetes Care · doi:10.2337/dc16-1353 · Cited by 94
Self-citationYamada, T., Shojima, N., Noma, H., Yamauchi, T., & Kadowaki, T. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13260 · Cited by 81
Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance
Apostolopoulou, M., Lambadiari, V., Roden, M., & Dimitriadis, G. D. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnae032 · Cited by 90
Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes
Kuhadiya, N. D., Ghanim, H., Mehta, A., Garg, M., Khan, S., Hejna, J., Torre, B., Makdissi, A., Chaudhuri, A., Batra, M., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1451 · Cited by 71
Musso, G., Sircana, A., Saba, F., Cassader, M., & Gambino, R. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003461 · Cited by 61
Famulla, S., Pieber, T. R., Eilbracht, J., Neubacher, D., Soleymanlou, N., Woerle, H. J., Broedl, U. C., & Kaspers, S. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0261 · Cited by 53
El Masri, D., Ghosh, S., & Jaber, L. A. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.01.004 · Cited by 45
Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
Snaith, J. R., Holmes-Walker, D. J., & Greenfield, J. R. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.11.007 · Cited by 45
Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus
Tan, X., Pan, X., Wu, X., Zheng, S., Chen, Y., Liu, D., & Zhang, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.975880 · Cited by 44
Bays, H. E., Kozlovski, P., Shao, Q., Proot, P., & Keefe, D. (2020) · Obesity · doi:10.1002/oby.22764 · Cited by 41
“Rare cases of ketoacidosis are reported with SGLT2 inhibitors (34-37) and also with the SGLT1 and 2 inhibitor sotagliflozin (23,27,28).”
BackgroundPatel, N. S., Van Name, M. A., Cengiz, E., Carria, L. R., Weinzimer, S. A., Tamborlane, W. V., & Sherr, J. L. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0267 · Cited by 30
Rao, L., Ren, C., Luo, S., Huang, C., & Li, X. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01686-x · Cited by 29
Bode, B. W., Cengiz, E., Wadwa, R. P., Banks, P., Danne, T., Kushner, J. A., McGuire, D. K., Peters, A. L., Strumph, P., & Sawhney, S. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0079 · Cited by 20
Metadata
- Authors
- Henry, R. R., Thakkar, P., Tong, C., Polidori, D., & Alba, M.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-10-20
- Volume
- 38
- Issue
- 12
- Pages
- 2258-2265
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2175219657
- Cited by
- 285
- References
- 26
- FWCI
- 22.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.